Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#1225 Everolimus in Patients (pts) with Advanced Lung Carcinoids: Evaluation of Median Progression Free Survival (PFS) and Median Time to First Dose Decrease or Discontinuation (DDD)

Introduction: Treatment of well-differentiated (WD) lung neuroendocrine tumors (NETs) is challenging. Everolimus (mTOR inhibitor) has shown encouraging results in digestive NETs but data about its activity on lung carcinoid are sparse.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Gianoncelli L, Guigay J, Caramella C, Borget I, Mir O,

Keywords: lung carcinoid, everolimus, mTOR inhibitor,

#998 Intra and Interobserver Reproducibility of CT and MRI for Measurement of Liver Metastasis as a Basis of RECIST Evaluation in Patients with Neuroendocrine Tumors

Introduction: The reliability of RECIST evaluation in patients with NET has not yet been analyzed.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Arfi Rouche J, Foulon S, Caramella C, Ternes N, Planchard D,

Keywords: CT, MRI, liver, metastasis, reproducibility, RECIST,

#759 Inter-and Intra-Observers Reproducibility of MRI for the Measurement of NET Liver Metastases

Introduction: Assessment of treatment is based on metastases size measurement.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Arfi Rouche J

Authors: Arfi Rouche J, Caramella C, Foulon S, Laplanche A, Baudin E,

Keywords: neuroendocrine, MRI, liver, metastase, reproducibility,

#706 Is There a Therapeutic Impact of Segmental Portal Hypertension on Advanced Pancreatic Neuroendocrine Tumors?

Introduction: Well-differenciated locally advanced Pancreatic Neuroendocrine Tumors (PNET) lead to significant local complications due to segmental portal hypertension (SPH).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Dumont F

Authors: Goudard Y, Dumont F, Caramella C, Goéré D, Honoré C,

Keywords: pancreatic neuroendocrine tumors, segmental portal hypertension, locally advanced,

#322 Effect of mTOR Inhibitor and Octreotide LAR on the Vascularization of Hepatic Metastases of Non-Pancreatic NETs: Preliminary Semi-Quantitative Dynamic MRI Assessment

Introduction: mTOR inhibitor Everolimus is a promising treatment in advanced NET. Its mechanisms include an antiangiogenic effect. Dynamic-enhanced MRI (D-MRI) enables the in vivo evaluation of tumoral perfusion.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Pham C, E. B, C. C, J. G, F. B,

Keywords: neuroendocrine tumor, mTOR, everolimus, octreotide, vascularisation, MRI,